Tachyon Presents Preclinical Data on the Company’s Novel KDM4 inhibitor, TACH101, at the 2022 AACR Annual Meeting
Retrieved on:
Friday, April 8, 2022
Oncology, Health, Other Health, Other Science, Research, Science, Biotechnology, Treatment, Company, Therapy, Germinal center B-cell like diffuse large B-cell lymphoma, Chromatin, Poster, IC50, B-cell lymphoma, Growth, Adult, ADME, AACR, American Association, Ernest, Probability, ABC, Cancer, CEO, Association, American Association for Cancer Research, PMBL, Science, GCB, Patient, Pharmaceutical industry, Medical imaging, Vaccine, DLBCL
Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private biotechnology company developing transformative cancer therapies against novel targets, today shared preclinical data for TACH101, the Companys first-in-class KDM4 inhibitor, at the American Association for Cancer Research ("AACR") Annual Meeting 2022.
Key Points:
- Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private biotechnology company developing transformative cancer therapies against novel targets, today shared preclinical data for TACH101, the Companys first-in-class KDM4 inhibitor, at the American Association for Cancer Research ("AACR") Annual Meeting 2022.
- TACH101 is an investigational agent for the potential treatment of adult patients with diffuse large B-cell lymphoma (DLBCL).
- These preclinical data on TACH101 highlight its anti-tumor activity in DLBCL, the most common and aggressive type of non-Hodgkin lymphoma, said Frank Perabo, M.D., Ph.D., CEO of Tachyon Therapuetics.
- AACR 2022 is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022.